Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.
Antineoplastic Agents
/ pharmacology
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Culture Techniques, Three Dimensional
/ methods
Cell Cycle
Cell Proliferation
Ciprofloxacin
/ pharmacology
Dose-Response Relationship, Drug
Drug Therapy, Combination
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Levofloxacin
/ pharmacology
Topoisomerase II Inhibitors
/ pharmacology
Tumor Cells, Cultured
Urogenital Neoplasms
/ drug therapy
3D cell culture
bladder cancer
ciprofloxacin
drug repositioning
levofloxacin
prostate cancer
topoisomerase
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Nov 2021
04 Nov 2021
Historique:
received:
13
05
2021
revised:
11
10
2021
accepted:
01
11
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Introducing new drugs for clinical application is a very difficult, long, drawn-out, and costly process, which is why drug repositioning is increasingly gaining in importance. The aim of this study was to analyze the cytotoxic properties of ciprofloxacin and levofloxacin on bladder and prostate cell lines in vitro. Bladder and prostate cancer cell lines together with their non-malignant counterparts were used in this study. In order to evaluate the cytotoxic effect of both drugs on tested cell lines, MTT assay, real-time cell growth analysis, apoptosis detection, cell cycle changes, molecular analysis, and 3D cultures were examined. Both fluoroquinolones exhibited a toxic effect on all of the tested cell lines. In the case of non-malignant cell lines, the cytotoxic effect was weaker, which was especially pronounced in the bladder cell line. A comparison of both fluoroquinolones showed the advantage of ciprofloxacin (lower doses of drug caused a stronger cytotoxic effect). Both fluoroquinolones led to an increase in late apoptotic cells and an inhibition of cell cycle mainly in the S phase. Molecular analysis showed changes in Our results suggest that both ciprofloxacin and levofloxacin may have great potential, especially in the supportive therapy of bladder cancer treatment. Taking into account the low costs of such therapy, fluoroquinolones seem to be ideal candidates for repositioning into bladder cancer therapeutics.
Identifiants
pubmed: 34769400
pii: ijms222111970
doi: 10.3390/ijms222111970
pmc: PMC8584631
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Topoisomerase II Inhibitors
0
Ciprofloxacin
5E8K9I0O4U
Levofloxacin
6GNT3Y5LMF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Nicolaus Copernicus University Grant for Young Scientists
ID : no. IND.WL.10.2021.
Références
Antibiotics (Basel). 2017 Nov 07;6(4):
pubmed: 29112154
Drug Saf. 2010 May 1;33(5):353-69
pubmed: 20397737
EMBO Mol Med. 2017 Jan;9(1):4-6
pubmed: 27852619
Int J Oncol. 2012 Dec;41(6):1943-9
pubmed: 23042104
J Urol. 1993 Nov;150(5 Pt 2):1718-21
pubmed: 8411457
J Antimicrob Chemother. 2001 Jul;48(1):37-45
pubmed: 11418511
Indian J Nephrol. 2019 Nov-Dec;29(6):424-426
pubmed: 31798226
Urology. 1999 Jul;54(1):56-61
pubmed: 10414727
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S180-6
pubmed: 11524717
Expert Opin Pharmacother. 2020 Apr;21(6):637-644
pubmed: 32004097
Curr Allergy Asthma Rep. 2017 Aug;17(8):56
pubmed: 28752367
Indian J Nephrol. 2017 May-Jun;27(3):231-233
pubmed: 28553048
Antimicrob Agents Chemother. 2000 Aug;44(8):2046-51
pubmed: 10898674
Med Hypotheses. 2012 Feb;78(2):235-8
pubmed: 22098728
Can J Infect Dis. 2002 Jan;13(1):54-61
pubmed: 18159374
Int J Antimicrob Agents. 2008 Oct;32(4):320-5
pubmed: 18715762
Cancer Chemother Pharmacol. 2011 Feb;67(2):275-84
pubmed: 20379816
Biomed Pharmacother. 2009 Mar;63(3):216-20
pubmed: 18328669
Int J Antimicrob Agents. 2006 Dec;28(6):551-9
pubmed: 17101261
Trends Microbiol. 2014 Aug;22(8):438-45
pubmed: 24842194
J Inorg Biochem. 2016 Jul;160:210-7
pubmed: 26993079
Cancer Lett. 1997 Nov 11;119(2):213-9
pubmed: 9570374
Clin Cancer Res. 2000 Mar;6(3):891-900
pubmed: 10741713
Am J Med. 1989 Nov 30;87(5A):57S-59S
pubmed: 2589386
J Chemother. 2008 Apr;20(2):213-8
pubmed: 18467248
Cancer. 1997 Dec 15;80(12):2263-7
pubmed: 9404703
Urol Int. 2012;88(3):343-9
pubmed: 22378292
Arch Ital Urol Androl. 2004 Dec;76(4):154-8
pubmed: 15693428
Biomed Pharmacother. 2019 Mar;111:934-946
pubmed: 30841473
J Antimicrob Chemother. 2003 May;51 Suppl 1:1-11
pubmed: 12702698
Int J Mol Sci. 2018 May 04;19(5):
pubmed: 29734647
Int Urol Nephrol. 2019 Jul;51(7):1089-1099
pubmed: 31154583
BMC Infect Dis. 2016 Nov 25;16(1):710
pubmed: 27887579
Curr Opin Microbiol. 1999 Oct;2(5):504-8
pubmed: 10508721
Oncol Res. 1994;6(12):569-79
pubmed: 7787250
Clin Infect Dis. 1999 Feb;28(2):299-308
pubmed: 10064248
Interdiscip Perspect Infect Dis. 2012;2012:976273
pubmed: 23097666
J Antimicrob Chemother. 1992 Mar;29(3):323-8
pubmed: 1592700
Asian J Androl. 2012 Nov;14(6):870-4
pubmed: 22864282
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1281-91
pubmed: 20214874
Antimicrob Agents Chemother. 1984 Nov;26(5):741-4
pubmed: 6517556
Int J Oncol. 2002 Jul;21(1):207-11
pubmed: 12063570
Med Sci Monit. 2010 Oct;16(10):RA218-23
pubmed: 20885364
Cancer Chemother Pharmacol. 2009 Aug;64(3):445-54
pubmed: 19104815
Urology. 2004 Mar;63(3):457-60
pubmed: 15028437
J Urol. 1996 Feb;155(2):757-62
pubmed: 8558720
F1000Res. 2018 Jul 25;7:
pubmed: 30109022
J Coll Physicians Surg Pak. 2011 Mar;21(3):157-60
pubmed: 21419022